Diabetes & Metabolism Journal

Review

Complications
Dyslipidemia in Patients with Chronic Kidney Disease: An Updated Overview: Sang Heon Suh, Soo Wan Kim; Diabetes Metab J. 2023;47(5):612-629. Published online July 24, 2023; DOI: https://doi.org/10.4093/dmj.2023.0067

13,563 View
1,002 Download
23 Web of Science
25 Crossref

Dyslipidemia is a potentially modifiable cardiovascular risk factor. Whereas the recommendations for the treatment target of dyslipidemia in the general population are being more and more rigorous, the 2013 Kidney Disease: Improving Global Outcomes clinical practice guideline for lipid management in chronic kidney disease (CKD) presented a relatively conservative approach with respect to the indication of lipid lowering therapy and therapeutic monitoring among the patients with CKD. This may be largely attributed to the lack of high-quality evidence derived from CKD population, among whom the overall feature of dyslipidemia is considerably distinctive to that of general population. In this review article, we cover the characteristic features of dyslipidemia and impact of dyslipidemia on cardiovascular outcomes in patients with CKD. We also review the current evidence on lipid lowering therapy to modify the risk of cardiovascular events in this population. We finally discuss the association between dyslipidemia and CKD progression and the potential strategy to delay the progression of CKD in relation to lipid lowering therapy.

Citations

Citations to this article as recorded by

Impact of remnant cholesterol on short-term and long-term prognosis in patients with prediabetes or diabetes undergoing coronary artery bypass grafting: a large-scale cohort study
Zhongchen Li, Chunyu Yu, Heng Zhang, Runze Chen, Yan Zhao, Zhe Zheng
Cardiovascular Diabetology.2025;[Epub] CrossRef
Effects of Tocotrienol on Cardiovascular Risk Markers in Patients With Chronic Kidney Disease: A Randomized Controlled Trial
Liana Trugilho, Lívia Alvarenga, Ludmila Cardozo, Bruna Paiva, Jessyca Brito, Isis Barboza, Jonatas Almeida, Juliana dos Anjos, Pramod Khosla, Marcelo Ribeiro-Alves, Denise Mafra, Eric Gumpricht
Journal of Nutrition and Metabolism.2025;[Epub] CrossRef
The Impact of Glomerular Disease on Dyslipidemia in Pediatric Patients Treated with Dialysis
Edward Zitnik, Elani Streja, Marciana Laster
Nutrients.2025; 17(3): 459. CrossRef
Diabetes, Chronic Kidney Disease, and Vascular Ulcers: Prevention Strategies and Clinical Implications
Stefano Mancin, Alfonso Zarrella, Fabio Petrelli, Simone Cosmai, Daniela Cattani, Diego Lopane, Sarah Scollo, Sara Morales Palomares, Marco Sguanci, Antonella Amendola, Giovanni Cangelosi, Beatrice Mazzoleni
Diabetology.2025; 6(2): 10. CrossRef
Cardiovascular disease burden and associated risk factors in chronic kidney disease
Roshan Bhandari, Srijan Pantha, Ghanashyam Pandey, Richa Paudyal
Indian Journal of Medical Sciences.2025; 0: 1. CrossRef
Association of the Triglyceride-Glucose Index with Body Composition and Laboratory Parameters in Chronic Kidney Disease Stages 3–5
Shan-Shan Xu, Yan-Meng Guan, Hong-Yun Xuan, Xiu-Fang Fan, Ping Lu, Li-Hai Hao
Risk Management and Healthcare Policy.2025; Volume 18: 903. CrossRef
The association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and pulmonary function: evidence from NHANES 2007–2012
Miaoyan Liu, Chaofeng Gao, Jinggeng Li, Yibo Zhang, Rui Gao, Chaoting Yang, Jian Zhang
Frontiers in Nutrition.2025;[Epub] CrossRef
Dietary butyric acid intake, kidney function, and survival: The National Health and Nutrition Examination Surveys, 2005–2018
Wei Tang, Zhengyi Long, Yang Xiao, Jingyun Du, Chenyuan Tang, JunXiang Chen, Can Hou
Clinical Nutrition ESPEN.2025; 67: 453. CrossRef
From fat to filter: the effect of adipose tissue-derived signals on kidney function
Nermin Ahmed, Carolina Dalmasso, Meghan B. Turner, Gertrude Arthur, Cole Cincinelli, Analia S. Loria
Nature Reviews Nephrology.2025;[Epub] CrossRef
CHANGES IN CENTRAL AORTIC PRESSURE AND ARTERIAL STIFFNESS IN YOUNG MEN WITH ARTERIAL HYPERTENSION AND CHRONIC KIDNEY DISEASE
O. M. Bilovol, I. I. Kniazkova, V. O. Golovachova, N. V. Kuzminova, D. О. Kіrienko, O. M. Kіrienko, L. P. Abramova
World of Medicine and Biology.2025; 21(91): 26. CrossRef
Analysis of the association between long-term exposure to low-dose ionizing radiation and dyslipidemia and its components in medical radiologists: The mediating role of inflammatory markers
Changyong Wen, Xiaolian Liu, Yiqing Lian, Weizhen Guo, Lingyu Zhang, Yanting Chen, Xin Lan, Mingfang Li, Sufen Zhang, Weixu Huang, Jianming Zou, Huifeng Chen
International Journal of Cardiology Cardiovascular Risk and Prevention.2025; 25: 200406. CrossRef
The protective effect of dietary sphingomyelin supplementation against impaired lipid metabolism in obese mice: a systematic review and meta-analysis of randomized controlled trials
Xiao-Yan Qin, Jie Pan, Yi-Na Liu, Hui-Min Luo, Fang Yang
Food, Nutrition and Health.2025;[Epub] CrossRef
Statin Therapy and Lipid Indices in Chronic Kidney Disease: A Systematic Review and Meta-analysis of Randomized Control Trials
Jafar Karami, Bahman Razi, Danyal Imani, Saeed Aslani, Mahdi Pakjoo, Mahdieh Fasihi, Keyhan Mohammadi, Amirhossein Sahebkar
Current Pharmaceutical Design.2024; 30(5): 362. CrossRef
Lipoprotein glomerulopathy with markedly increased arterial stiffness successfully treated with a combination of fenofibrate and losartan: a case report
Junichiro Kato, Hideo Okonogi, Go Kanzaki, Haruki Katsumata, Yasuyuki Nakada, Makoto Sagasaki, Kazumasa Komine, Kenji Ito, Takao Saito, Akira Matsunaga, Koh Tokutou, Kazuho Honda, Nobuo Tsuboi, Takashi Yokoo
BMC Nephrology.2024;[Epub] CrossRef
Atherogenic index of plasma: a new indicator for assessing the short-term mortality of patients with acute decompensated heart failure
Meng Yu, Hongyi Yang, Maobin Kuang, Jiajun Qiu, Changhui Yu, Guobo Xie, Guotai Sheng, Yang Zou
Frontiers in Endocrinology.2024;[Epub] CrossRef
Association between lipid accumulation product index and chronic kidney disease: A systematic review and meta-analysis
Feixiang Wu, Chenmin Cui, Junping Wu, Yunqing Wang
Experimental and Therapeutic Medicine.2024;[Epub] CrossRef
Potential impact of sodium glucose co-transporter (SGLT2) inhibitors on cholesterol fractions in stage 3 chronic kidney disease
Rabab Mahmoud Ahmed, Nehal Kamal Rakha, Ahmed Yousry, Amin Roshdy Soliman
The Egyptian Journal of Internal Medicine.2024;[Epub] CrossRef
Pulmonary Hypertension in Hemodialysis Patients and Its Determinants: A Hospital Based Cross-Sectional Study
Qingfei Yu, Qin Zhang
International Journal of General Medicine.2024; Volume 17: 3919. CrossRef
Relationship Between Serum Uromodulin as a Marker of Kidney Damage and Metabolic Status in Patients with Chronic Kidney Disease of Non-Diabetic Etiology
Radmila Žeravica, Branislava Ilinčić, Dragan Burić, Ana Jakovljević, Veljko Crnobrnja, Dalibor Ilić, Marija Vukmirović Papuga
International Journal of Molecular Sciences.2024; 25(20): 11159. CrossRef
Dyslipidemia in Peritoneal Dialysis: Implications for Peritoneal Membrane Function and Patient Outcomes
Natalia Stepanova
Biomedicines.2024; 12(10): 2377. CrossRef
Causal associations between kidney function and aortic valve stenosis: a bidirectional Mendelian randomization analysis
Wanqian Pan, Le Zhou, Rui Han, Xiaojiao Du, Weixiang Chen, Tingbo Jiang
Renal Failure.2024;[Epub] CrossRef
U-shaped association between dietary niacin intake and chronic kidney disease among US elderly: a nationwide cross-sectional study
Zhouzhou Xie, Shansen Peng, Gejun Ou, Xiaoqi Zhou, Guihao Zhang, Huiming Jiang, Tianhui Zhang, Nanhui Chen
Frontiers in Endocrinology.2024;[Epub] CrossRef
Association between dried fruit intake and kidney function: research from univariate and multivariate Mendelian randomized studies
Yuhang Gao, Xinghai Yue, Wanchao Zhao, Fang Yuan
Frontiers in Nutrition.2024;[Epub] CrossRef
The Dual Burden: Exploring Cardiovascular Complications in Chronic Kidney Disease
Alfredo Caturano, Raffaele Galiero, Maria Rocco, Giuseppina Tagliaferri, Alessia Piacevole, Davide Nilo, Giovanni Di Lorenzo, Celestino Sardu, Vincenzo Russo, Erica Vetrano, Marcellino Monda, Raffaele Marfella, Luca Rinaldi, Ferdinando Carlo Sasso
Biomolecules.2024; 14(11): 1393. CrossRef
Association between the EHBP1 SNPs and dyslipidemia in the end-stage renal disease patients with dialysis in Chinese Han population
Yan-Fei Lai, Zhong-E Liang, Chun-Xiang Wu, Min Zhang, Zong-Hu Shi, Xiao-Yan Meng, Chun-Xiao Liu
Lipids in Health and Disease.2024;[Epub] CrossRef

Original Article

Cardiovascular Risk/Epidemiology
Glycemic Control and Adverse Clinical Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus: Results from KNOW-CKD: Ga Young Heo, Hee Byung Koh, Hyung Woo Kim, Jung Tak Park, Tae-Hyun Yoo, Shin-Wook Kang, Jayoun Kim, Soo Wan Kim, Yeong Hoon Kim, Su Ah Sung, Kook-Hwan Oh, Seung Hyeok Han; Diabetes Metab J. 2023;47(4):535-546. Published online April 25, 2023; DOI: https://doi.org/10.4093/dmj.2022.0112

5,326 View
223 Download
6 Web of Science
5 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
The optimal level of glycosylated hemoglobin (HbA1c) to prevent adverse clinical outcomes is unknown in patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM).
Methods
We analyzed 707 patients with CKD G1-G5 without kidney replacement therapy and T2DM from the KoreaN Cohort Study for Outcome in Patients With Chronic Kidney Disease (KNOW-CKD), a nationwide prospective cohort study. The main predictor was time-varying HbA1c level at each visit. The primary outcome was a composite of development of major adverse cardiovascular events (MACEs) or all-cause mortality. Secondary outcomes included the individual endpoint of MACEs, all-cause mortality, and CKD progression. CKD progression was defined as a ≥50% decline in the estimated glomerular filtration rate from baseline or the onset of end-stage kidney disease.
Results
During a median follow-up of 4.8 years, the primary outcome occurred in 129 (18.2%) patients. In time-varying Cox model, the adjusted hazard ratios (aHRs) for the primary outcome were 1.59 (95% confidence interval [CI], 1.01 to 2.49) and 1.99 (95% CI, 1.24 to 3.19) for HbA1c levels of 7.0%–7.9% and ≥8.0%, respectively, compared with <7.0%. Additional analysis of baseline HbA1c levels yielded a similar graded association. In secondary outcome analyses, the aHRs for the corresponding HbA1c categories were 2.17 (95% CI, 1.20 to 3.95) and 2.26 (95% CI, 1.17 to 4.37) for MACE, and 1.36 (95% CI, 0.68 to 2.72) and 2.08 (95% CI, 1.06 to 4.05) for all-cause mortality. However, the risk of CKD progression did not differ between the three groups.
Conclusion
This study showed that higher HbA1c levels were associated with an increased risk of MACE and mortality in patients with CKD and T2DM.

Citations

Citations to this article as recorded by

Unveiling the utility of artificial intelligence for prediction, diagnosis, and progression of diabetic kidney disease: an evidence-based systematic review and meta-analysis
Sagar Dholariya, Siddhartha Dutta, Amit Sonagra, Mehul Kaliya, Ragini Singh, Deepak Parchwani, Anita Motiani
Current Medical Research and Opinion.2024; 40(12): 2025. CrossRef
Non-Alcoholic Fatty Liver Disease and Its Association with Kidney and Cardiovascular Outcomes in Moderate to Advanced Chronic Kidney Disease
Cheol Ho Park, Hyunsun Lim, Youn Nam Kim, Jae Young Kim, Hyung Woo Kim, Tae Ik Chang, Seung Hyeok Han
American Journal of Nephrology.2024; : 1. CrossRef
The Beneficial Effect of Glycemic Control against Adverse Outcomes in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
Dong-Hwa Lee
Diabetes & Metabolism Journal.2023; 47(4): 484. CrossRef
Prevalence and predictors of chronic kidney disease among type 2 diabetic patients worldwide, systematic review and meta-analysis
Eneyew Talie Fenta, Habitu Birhan Eshetu, Natnael Kebede, Eyob Ketema Bogale, Amare Zewdie, Tadele Derbew Kassie, Tadele Fentabil Anagaw, Elyas Melaku Mazengia, Sintayehu Shiferaw Gelaw
Diabetology & Metabolic Syndrome.2023;[Epub] CrossRef
Efficacy and safety of teneligliptin in patients with type 2 diabetes mellitus: a Bayesian network meta-analysis
Miao Zhu, Ruifang Guan, Guo Ma
Frontiers in Endocrinology.2023;[Epub] CrossRef

First
Prev
Page of 1
Next
Last

Search